Orexigen Therapeutic (OREX) 3.46 $OREX
Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Wed Sep 07, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation is scheduled for Monday, September 12, at 9:35 a.m. ET. The conference, sponsored by H.C. Wainwright & Co., will take place in New York City on September 11 - 13, 2016.
OREX: 3.46 (+0.02)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.46 (+0.02), VRX: 27.28 (-0.09), ANIP: 64.30 (+0.50), PCRX: 42.33 (+1.79)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)
PR Newswire - Tue Aug 30, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone HCl / bupropion HCl extended release) in Canada. Under the terms of the agreement between Valeant and Orexigen's wholly owned subsidiary Orexigen Therapeutics Ireland Ltd., Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.
OREX: 3.46 (+0.02), VRX.TO: 36.09 (+0.06)
Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
PR Newswire - Thu Aug 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
OREX: 3.46 (+0.02)
Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization
PR Newswire - Mon Aug 01, 7:31AM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropion HCl extended release) and relaunched Contrave with the Company's own sales organization. The acquisition was originally announced March 2016 and was completed two months ahead of schedule.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios FarmaceÌuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain
PR Newswire - Mon Aug 01, 7:30AM CDT
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Laboratorios FarmaceÌuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (greater-than or equal to 18 years) with an initial Body Mass Index (BMI) of greater-than or equal to 30 kg/m2 (obese), or greater-than or equal to 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). Founded in 1946 and headquartered in Madrid, Spain, ROVI has a diversified pharmaceutical portfolio.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Jun 22, 3:30PM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase a total of 232,500 shares of common stock to six new employees. Additionally, the Compensation Committee approved two individually negotiated inducement stock option grants, including options to purchase 225,000 shares of common stock to Salma Jutt-Eghbali, Head of Commercial Innovation, and options to purchase 45,000 shares of common stock to Kim Burns, National Account Executive.
OREX: 3.46 (+0.02)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.46 (+0.02), RTRX: 24.25 (+0.02), VVUS: 1.07 (+0.01), ARNA: 1.66 (-0.08)
Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO
PR Newswire - Wed Jun 08, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the promotions of Thomas Cannell, D.V.M., to Executive Vice President, Chief Operating Officer, and President of Global Commercial Products and Jason Keyes to Senior Vice President, Chief Financial Officer.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation
PR Newswire - Wed Jun 08, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the currently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.
OREX: 3.46 (+0.02)
Orexigen Announces Upcoming Presentations at European Obesity Summit 2016
PR Newswire - Fri May 27, 3:10PM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the European Obesity Summit 2016 at The Swedish Exhibition and Congress Centre in Gothenburg, Sweden on June 1-4, 2016.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
PR Newswire - Fri May 27, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. Dr. Weber served as Chairman from 2002 until earlier this year. From November 2008 until March 2009, Dr. Weber also served as interim President and Chief Executive Officer.
OREX: 3.46 (+0.02)
Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
PR Newswire - Mon May 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Deborah A. Jorn to its Board of Directors, effective immediately. The Company also announced Dr. Preston Klassen has resigned to pursue other interests in drug development with a private company. Peter Flynn, PhD has been appointed as Senior Vice President, Head of Development, Regulatory Affairs and Safety, while Toni Foster will continue in her role as Senior Vice President, Project Management Office and Clinical Operations.
OREX: 3.46 (+0.02), JNJ: 118.25 (-0.38)
Orexigen reports 1Q loss
Automated Insights - Wed May 04, 3:51PM CDT
LA JOLLA, Calif. (AP) _ Orexigen Therapeutics Inc. (OREX) on Wednesday reported a loss of $22.3 million in its first quarter.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire - Wed May 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
OREX: 3.46 (+0.02)
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 4:30PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The discussion is scheduled for Tuesday, May 10th, at 1:00 p.m. Pacific Time.
OREX: 3.46 (+0.02)
Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Wed Sep 07, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation is scheduled for Monday, September 12, at 9:35 a.m. ET. The conference, sponsored by H.C. Wainwright & Co., will take place in New York City on September 11 - 13, 2016.
OREX: 3.46 (+0.02)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.46 (+0.02), VRX: 27.28 (-0.09), ANIP: 64.30 (+0.50), PCRX: 42.33 (+1.79)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)
PR Newswire - Tue Aug 30, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone HCl / bupropion HCl extended release) in Canada. Under the terms of the agreement between Valeant and Orexigen's wholly owned subsidiary Orexigen Therapeutics Ireland Ltd., Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.
OREX: 3.46 (+0.02), VRX.TO: 36.09 (+0.06)
Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
PR Newswire - Thu Aug 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
OREX: 3.46 (+0.02)
Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization
PR Newswire - Mon Aug 01, 7:31AM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropion HCl extended release) and relaunched Contrave with the Company's own sales organization. The acquisition was originally announced March 2016 and was completed two months ahead of schedule.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios FarmaceÌuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain
PR Newswire - Mon Aug 01, 7:30AM CDT
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Laboratorios FarmaceÌuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (greater-than or equal to 18 years) with an initial Body Mass Index (BMI) of greater-than or equal to 30 kg/m2 (obese), or greater-than or equal to 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). Founded in 1946 and headquartered in Madrid, Spain, ROVI has a diversified pharmaceutical portfolio.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Jun 22, 3:30PM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase a total of 232,500 shares of common stock to six new employees. Additionally, the Compensation Committee approved two individually negotiated inducement stock option grants, including options to purchase 225,000 shares of common stock to Salma Jutt-Eghbali, Head of Commercial Innovation, and options to purchase 45,000 shares of common stock to Kim Burns, National Account Executive.
OREX: 3.46 (+0.02)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.46 (+0.02), RTRX: 24.25 (+0.02), VVUS: 1.07 (+0.01), ARNA: 1.66 (-0.08)
Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO
PR Newswire - Wed Jun 08, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the promotions of Thomas Cannell, D.V.M., to Executive Vice President, Chief Operating Officer, and President of Global Commercial Products and Jason Keyes to Senior Vice President, Chief Financial Officer.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation
PR Newswire - Wed Jun 08, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the currently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.
OREX: 3.46 (+0.02)
Orexigen Announces Upcoming Presentations at European Obesity Summit 2016
PR Newswire - Fri May 27, 3:10PM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the European Obesity Summit 2016 at The Swedish Exhibition and Congress Centre in Gothenburg, Sweden on June 1-4, 2016.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
PR Newswire - Fri May 27, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. Dr. Weber served as Chairman from 2002 until earlier this year. From November 2008 until March 2009, Dr. Weber also served as interim President and Chief Executive Officer.
OREX: 3.46 (+0.02)
Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
PR Newswire - Mon May 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Deborah A. Jorn to its Board of Directors, effective immediately. The Company also announced Dr. Preston Klassen has resigned to pursue other interests in drug development with a private company. Peter Flynn, PhD has been appointed as Senior Vice President, Head of Development, Regulatory Affairs and Safety, while Toni Foster will continue in her role as Senior Vice President, Project Management Office and Clinical Operations.
OREX: 3.46 (+0.02), JNJ: 118.25 (-0.38)
Orexigen reports 1Q loss
Automated Insights - Wed May 04, 3:51PM CDT
LA JOLLA, Calif. (AP) _ Orexigen Therapeutics Inc. (OREX) on Wednesday reported a loss of $22.3 million in its first quarter.
OREX: 3.46 (+0.02)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire - Wed May 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
OREX: 3.46 (+0.02)
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 4:30PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The discussion is scheduled for Tuesday, May 10th, at 1:00 p.m. Pacific Time.
OREX: 3.46 (+0.02)
